13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001608126
Total reported value
$2.8B
$2.8B
26 檔
7.4%
The Q1 2024 SEC filing reveals that Finepoint Capital LP held a total portfolio value of $2.8B, covering 26 public equity positions.
During Q1 2024, Finepoint Capital LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including LBRDK, SWTXUSD, ASND) accounted for 7.4% of total reported equity market value during Q1 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LBRDK | Liberty Broadband-c | Stock-Comm Services | 27.68% | — | +922.58% | |
| 2 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 7.48% | — | +6.39% | |
| 3 | ASND | Ascendis Pharma A/S | Stock-Other | 6.81% | — | +7.27% | |
| 4 | ARVN | Arvinas Inc | Stock-Other | 5.71% | — | +6.82% | |
| 5 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 5.60% | — | +9.72% | |
| 6 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 5.26% | — | +9.01% | |
| 7 | ARGX | Argenx Se - Adr | Stock-Healthcare | 5.05% | — | — | |
| 8 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 4.65% | — | -59.67% | |
| 9 | CYTK | Cytokinetics Inc | Stock-Healthcare | 4.28% | — | -44.86% | |
| 10 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 4.16% | — | +9.83% | |
| 11 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 3.99% | — | +9.20% | |
| 12 | EYPT | Eyepoint Inc | Stock-Other | 3.48% | — | — | |
| 13 | DISH 0 12-15-25Bond | Dish Network CORP | Bond | 3.45% | — | — | |
| 14 | SLDB | Solid Biosciences Inc | Stock-Other | 3.28% | — | — | |
| 15 | TVTX | Travere Therapeutics Inc | Stock-Other | 3.26% | — | +14.90% | |
| 16 | RLAY | Relay Therapeutics Inc | Stock-Other | 3.17% | — | +13.07% | |
| 17 | PRTA | Prothena Corporation plc | Stock-Other | 2.56% | — | +15.20% | |
| 18 | ✓ | Stock-Other | 0.04% | — | — | ||
| 19 | ✓ | Moneyhero Limited | Stock-Other | 0.03% | — | — | |
| 20 | ✓ | Calidi Biotherapeutics Inc | Stock-Other | 0.02% | — | — | |
| 21 | CNDAW | Concord Acquisition A -cw28 | Stock-Other | 0.01% | — | — | |
| 22 | ✓ | Compass Digital Acquisition Co | Stock-Other | 0.01% | — | — | |
| 23 | CLDWW | Calidi Biotherapeutics -cw23 | Stock-Other | 0.01% | — | — | |
| 24 | ✓ | Swiftmerge Acquisition CORP | Stock-Other | 0.01% | — | — | |
| 25 | ✓ | Summit Healthcare Acquisition | Stock-Other | 0.01% | — | — | |
| 26 | ✓ | Marblegate Acquisition CORP | Stock-Other | — | — | — |
According to official SEC Form 13F filings, Finepoint Capital LP reported a total U.S. public equity portfolio value of $2.8B across 26 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
During Q1 2024, Finepoint Capital LP's top holdings by market value included LBRDK (27.7%)、SWTXUSD (7.5%)、ASND (6.8%). The largest single position, LBRDK, represented 27.7% of total portfolio value.
In Q1 2024, Finepoint Capital LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.